Evaluation of mobilized peripheral blood CD34(+) cells from patients with severe coronary artery disease as a source of endothelial progenitor cells

Cytotherapy. 2010 Apr;12(2):178-89. doi: 10.3109/14653240903493409.

Abstract

Background aims: The distinction between hematopoietic stem cells (HSC) and endothelial progenitor cells (EPC) is poorly defined. Co-expression of CD34 antigen with vascular endothelial growth factor (VEGF) receptor (VEGFR2) is currently used to define EPC ( 1 ).

Methods: We evaluated the phenotypic and genomic characteristics of peripheral blood-derived CD34(+) cells in 22 granulocyte-colony-stimulating factor (G-CSF)-mobilized patients with severe coronary artery disease and assessed the influence of cell selection and storage on CD34(+) cell characteristics.

Results: The median CD34(+) cell contents in the products before and after enrichment with the Isolex 300i Magnetic Cell Selection System were 0.2% and 82.5%, respectively. Cell-cycle analysis showed that 80% of CD34(+) cells were in G0 stage; 70% of the isolated CD34(+) cells co-expressed CD133, a marker for more immature progenitors. However, less than 5% of the isolated CD34(+) cells co-expressed the notch receptor Jagged-1 (CD339) and only 2% of the isolated CD34(+) population were positive for VEGFR2 (CD309). Molecular assessment of the isolated CD34(+) cells demonstrated extremely low expression of VEGFR2 and endothelial nitric oxide synthase (eNOS) and high expression of VEGF-A. Overnight storage at 4 degrees C did not significantly affect CD34(+) cell counts and viability. Storage in liquid nitrogen for 7 weeks did not affect the percentage of CD34(+) cells but was associated with a 26% drop in cell viability.

Conclusions: We have demonstrated that the majority of isolated CD34(+) cells consist of immature and quiescent cells that lack prototypic markers of EPC. High VEGF-A gene expression might be one of the mechanisms for CD34(+) cell-induced angiogenesis.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • AC133 Antigen
  • Aged
  • Angiogenic Proteins / genetics
  • Angiogenic Proteins / metabolism
  • Antigens, CD / genetics
  • Antigens, CD / metabolism
  • Antigens, CD34 / metabolism*
  • Biomarkers / metabolism
  • Cell Count
  • Cell Cycle
  • Cell Separation
  • Cell Survival
  • Clinical Trials, Phase II as Topic
  • Coronary Artery Disease / blood*
  • Coronary Artery Disease / pathology
  • Endothelial Cells / cytology*
  • Female
  • Flow Cytometry
  • Gene Expression Regulation
  • Glycoproteins / genetics
  • Glycoproteins / metabolism
  • Hematopoietic Stem Cell Mobilization*
  • Hematopoietic Stem Cells / cytology*
  • Hematopoietic Stem Cells / metabolism
  • Humans
  • Immunohistochemistry
  • Male
  • Middle Aged
  • Peptides / genetics
  • Peptides / metabolism
  • Reverse Transcriptase Polymerase Chain Reaction
  • Transplantation, Autologous
  • Vascular Endothelial Growth Factor Receptor-2 / genetics
  • Vascular Endothelial Growth Factor Receptor-2 / metabolism

Substances

  • AC133 Antigen
  • Angiogenic Proteins
  • Antigens, CD
  • Antigens, CD34
  • Biomarkers
  • Glycoproteins
  • PROM1 protein, human
  • Peptides
  • Vascular Endothelial Growth Factor Receptor-2